Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy

Detalhes bibliográficos
Autor(a) principal: Azevedo Kauppila, Linda
Data de Publicação: 2021
Outros Autores: Silva, Daniela, Ferreira, Joaquim J
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/48187
Resumo: © 2021 Azevedo Kauppila et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
id RCAP_4d96e7834af069fcc13db9d11e436703
oai_identifier_str oai:repositorio.ul.pt:10451/48187
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapyParkinson’s diseaseOopicaponeMotor fluctuationsCOMT inhibitorSafetyTolerability© 2021 Azevedo Kauppila et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Parkinson’s disease (PD) is a prevalent neurodegenerative disorder, and levodopa (L-dopa) remains the most efficacious drug treatment for PD and a gold-standard for symptom control. Nonetheless, a significant majority of PD patients develop motor fluctuations over their disease course, with a significant impact on quality-of-life, meaning control of such complications translates into a fundamental clinical need. Catechol-O-methyl transferase (COMT) inhibitors (COMT-i) are used as first-line adjuvant therapy to L-dopa for endof-dose (EoD) motor fluctuations, since they increase L-dopa availability in the brain by inhibiting its peripheral metabolism. Opicapone (OPC), a once-daily, long-acting COMT-i, is the most recent and potent of its class, having been licensed in Europe in 2016 as an add-on to preparations of L-dopa/DOPA decarboxylase inhibitors in PD patients with EoD motor fluctuations. More recently, it has also received approval in the USA and Japan in 2020. Two high-quality positive efficacy studies (double-blind Phase III clinical trials) established OPC efficacy with significant reduction in OFF time (average 60 minutes vs placebo), without concomitant increase of distressing dyskinesias during ON time. These beneficial effects were sustained in open-label extension studies, without unexpected safety issues or adverse events, with dyskinesia having been the most frequent complaint. OPC also avoids liver toxicity and gastrointestinal issues compared with previous COMT-i. In this review, we aimed to cover OPC’s lifecycle (synthesis to commercialization), its clinical pharmacological data, safety, tolerability and pharmacovigilance evidence, and discuss its role in the management of motor fluctuations in PD as well as its emerging place in international recommendations.DovepressRepositório da Universidade de LisboaAzevedo Kauppila, LindaSilva, DanielaFerreira, Joaquim J2021-05-26T15:10:49Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/48187engDegener Neurol Neuromuscul Dis. 2021 May 11;11:29-4010.2147/DNND.S2567221179-9900info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:51:24Zoai:repositorio.ul.pt:10451/48187Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:00:04.708181Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
title Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
spellingShingle Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
Azevedo Kauppila, Linda
Parkinson’s disease
Oopicapone
Motor fluctuations
COMT inhibitor
Safety
Tolerability
title_short Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
title_full Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
title_fullStr Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
title_full_unstemmed Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
title_sort Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy
author Azevedo Kauppila, Linda
author_facet Azevedo Kauppila, Linda
Silva, Daniela
Ferreira, Joaquim J
author_role author
author2 Silva, Daniela
Ferreira, Joaquim J
author2_role author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Azevedo Kauppila, Linda
Silva, Daniela
Ferreira, Joaquim J
dc.subject.por.fl_str_mv Parkinson’s disease
Oopicapone
Motor fluctuations
COMT inhibitor
Safety
Tolerability
topic Parkinson’s disease
Oopicapone
Motor fluctuations
COMT inhibitor
Safety
Tolerability
description © 2021 Azevedo Kauppila et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
publishDate 2021
dc.date.none.fl_str_mv 2021-05-26T15:10:49Z
2021
2021-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/48187
url http://hdl.handle.net/10451/48187
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Degener Neurol Neuromuscul Dis. 2021 May 11;11:29-40
10.2147/DNND.S256722
1179-9900
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Dovepress
publisher.none.fl_str_mv Dovepress
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134547869171712

Registros relacionados